Capacity expansion across segments to steer growth beyond FY26Xanthine segment during the quarter witnessed growth mainly on back of increased capacity utilization to 6000 MTPA. The company remains on track to expand its capacity to 9000 MTPA by Q1FY26. Prices of xanthine have improved in spot market as per management. We believe APL to focus more on grabbing the larger wallet share across Pharma and beverage customers in future. We also keep tab on the opportunities emanating from China's anti-involution drive especially on the pricing front. On the CDMO front, the management has guided for 40-50% growth...